AIDS Drug Assistance Programs in the era of routine HIV testing
AIDS Drug Assistance Programs in the era of routine HIV testing
复制标题
DOI：
10.1086/590936
复制
发表时间：
2008-09-01
影响因子：
11.8
通讯作者：
Walensky, Rochelle P.
中科院分区：
文献类型：
--
作者：
Bassett, Ingrid V.;Farel, Claire;Walensky, Rochelle P.
艾滋病[获得性免疫缺陷综合症]药物援助方案，在更大的瑞安白色方案内运作，是以州为基础的自由裁量方案，为感染人类免疫缺陷病毒（艾滋病毒）的低收入和无保险的个人提供药物“安全网”。尽管艾滋病药物援助计划和为艾滋病毒感染者提供护理的初级保健系统已经面临财政压力，但疾病控制和预防中心最近发布了指导方针，建议普遍进行艾滋病毒检测，以帮助确定美国估计有30万人不知道他们感染了艾滋病毒。随着同时感染丙型肝炎病毒的艾滋病毒/艾滋病感染者人数的增加，以及护理的成本和复杂性的增加，目前艾滋病毒护理系统的可持续性需要根据新的检测准则进行重新评估。我们研究艾滋病药物援助计划的现状，讨论疾病控制和预防中心的指导方针已经过度伸展瑞安白色计划的影响，并考虑联邦政府支持的国家计划，以确保高质量，高效率的艾滋病毒护理低收入的艾滋病毒感染的美国人。
AIDS [Acquired Immunodeficiency Syndrome] Drug Assistance Programs, operating within the larger Ryan White Program, are state-based, discretionary programs that provide a drug "safety net" for low-income and uninsured individuals infected with human immunodeficiency virus (HIV). Although the AIDS Drug Assistance Programs and the primary care system that provides care for patients with HIV infection are already financially stressed, the Centers for Disease Control and Prevention recently issued guidelines recommending universal HIV testing to help identify the estimated 300,000 individuals in the United States who are unaware that they are infected with HIV. As the number of people living with HIV/AIDS who are coinfected with hepatitis C virus has grown and the cost and complexity of care have increased, the sustainability of the current HIV care system requires a reevaluation in light of the new testing guidelines. We examine the current state of the AIDS Drug Assistance Programs, discuss the implications of the Centers for Disease Control and Prevention guidelines for the already overstretched Ryan White Program, and consider a federally supported national program to ensure high-quality, efficient HIV care for low-income HIV-infected Americans.